Work

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms

Year: 2025

Type: article

Abstract: ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2 V617F ‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2 V617F ‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke ( p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality ( p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation ( p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β ( p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2 V617F ‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group ( p < 0.05). Conclusion AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2 V617F ‐positive MPN.

Source: Cancer Medicine

DOI: 10.1002/cam4.71015